Puja Sapra, Senior Vice President Head R&D Biologics Engineering and Oncology Targeted Discovery at AstraZeneca, shared on LinkedIn:
“Biologic medicines are among the most complex therapies, and designing them has traditionally been an intensive, iterative process of screening vast numbers of molecules to find the rare few with the right properties.
At AstraZeneca, AI is now embedded across our biologics discovery pipeline, informing scientists at every stage.
We generate and evaluate molecule libraries in silico, predict molecular properties before making them in the lab, allowing us to focus development on the candidates most likely to succeed.
Our data is central to this. With our intentionally diverse portfolio spanning multiple disease areas and drug types, built over decades, we can fine-tune frontier AI models with richer, more representative biological data.
Looking ahead, we are making encouraging early progress toward de novo biologic design: with the goal to generate entirely new molecules from scratch that we take through to clinical therapeutic candidates.
And as AI capabilities mature, we are increasingly able to pursue disease targets once considered impossible to reach with medicines.
Read my contribution to this piece in MIT Technology Review exploring how AI is reshaping biologics discovery and what the future of medicine design could look like.
I hope you find it a useful read.”
How AI helps scientists design the next generation of medicines
Other articles about AI and AstraZeneca on OncoDaily.